Bristol Myers Squibb secured regulatory approval to extend Breyanzi’s indication to include third‑line marginal zone lymphoma, making it the first CAR‑T therapy cleared for that rare non‑Hodgkin lymphoma subtype. The approval follows submission of clinical data supporting activity in the slow‑growing disease and adds to Breyanzi’s growing suite of hematologic indications. The label expansion broadens the commercial footprint for an already marketed CAR‑T and may influence payer negotiations and treatment sequencing in indolent B‑cell malignancies. It also highlights the continued regulatory momentum for autologous cell therapies in niche oncology indications.